Clinical & Scientific Resources
Clinical Studies
2016
Avulux Migraine and Light Sensitivity Pilot Study Published in the Journal of Clinical Neuroscience
A lens blocking light specifically at the 480nm wavelength was compared to another lens blocking light at 620nm to measure their efficacy at reducing the impact of a migraine attack as measured by the HIT-6 Test, a test specifically designed to measure the effect of migraine attacks on quality of life and activities of daily living. More than half 19/37 subjects wearing one of these lenses showed at least a one level clinical improvement, opening the door to the development of the current Avulux lens.
Published research: https://pubmed.ncbi.nlm.nih.gov/26935748/
2020
Double Blind, Independently Run Randomized Trial
In this study, the Avulux lens was compared with a true clear sham lens that did not significantly block any of the wavelengths that are associated with migraine attacks. 79 subjects completed the three week study that measured migraine pain level, using an 11 point pain scale (a drop of approximately 1.8 points was considered clinically significant as validated by many other unrelated trials), at the onset of a migraine attack, and both 2 hours and 4 hours after application of the Avulux or sham lens. The presence or absence of light sensitivity was also measured at both 2 and 4 hours after the attack. The results demonstrated that if the Avulux lens was applied within the first hour after the onset of a migraine attack, if all headaches that a study subject had during the clinical trial period were included, and if no abortive medications were taken, that Avulux was both statistically and clinically superior to the sham lens. This is the highest scientific standard of efficacy.
Trial information: https://clinicaltrials.gov/ct2/show/NCT04341298
Peer reviewed publication: Journal of Clinical Neuroscience.
Patents
Patent No: 9759848
Intended Use: Avulux Glasses, which absorb specific wavelengths of light, may, as part of a healthy lifestyle, help people living with migraine. Avulux Glasses are marketed pursuant to FDA’s policy for general wellness tools, and are not FDA-cleared or approved to treat, prevent, or cure any disease or disorder.
